Last reviewed · How we verify
Teolit (TESTOLACTONE)
At a glance
| Generic name | TESTOLACTONE |
|---|---|
| Drug class | Aromatase Inhibitor |
| Target | Aromatase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1969 |
Approved indications
- Carcinoma of female breast
Common side effects
Key clinical trials
- Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia (PHASE3)
- Sex Steroids and the Serotonin Transporter (PHASE4)
- Treatment of Boys With Precocious Puberty (PHASE2)
- Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |